人卵巢癌组织中BRCA1、PRP13、TUBB3及ERCC1基因表达及其与化疗耐药的关系

Association of BRCA1,PRP13,TUBB3 and ERCC1 gene expression with drug resistance in human ovarian cancer

目的分析乳腺癌易感基因1(breast cancer susceptibility gene 1,BRCA1)、富脯氨酸多肽(proline-rich polypeptide 13,PRP13)、β-微管蛋白Ⅲ型(classⅢbeta-tubulin,TUBB3)及核苷酸切除修复交叉互补基因1(excision repair cross-complementation 1,ERCC1)在人卵巢癌组织中的表达及其与卵巢癌化疗耐药的关系。方法选取80例卵巢上皮癌组织,其中23例原发性卵巢上皮癌组织,57例复发性卵巢上皮癌组织。57例复发性卵巢上皮癌患者中32例初次复发为铂类敏感型复发,25例为铂类耐药型复发。采用荧光定量PCR技术检测所有癌组织标本中BRCA1、PRP13、TUBB3及ERCC1基因的表达水平,并根据结果分析卵巢癌化疗耐药机制。结果原发性和复发性卵巢上皮癌组织间BRCA1、PRP13、TUBB3及ERCC1耐药基因相对表达量比较,差异均无统计学意义(均P>0.05)。敏感型与耐药型复发性卵巢上皮癌患者组织中BRCA1和ERCC1相对表达量比较,差异均具有统计学意义(均P<0.05),PRP13和TUBB3的表达水平比较,差异均无统计学意义(均P>0.05)。结论 BRCA1、PRP13、TUBB3及ERCC1基因在原发性和复发性人卵巢癌组织中的表达水平差异不大,但BRCA1和ERCC1的表达水平与复发性卵巢上皮癌患者耐药性产生相关。

Objective To investigate the association of breast cancer susceptibility gene 1（ BRCA1）,proline-rich polypeptide 13（ PRP13）,class Ⅲ beta-tubulin（ TUBB3） and nucleotide excision repair cross-complementation 1（ ERCC1） gene expression with chemotherapy resistance in human ovarian cancer. Methods Eighty samples of epithelial ovarian cancer tissues were collected,including 23 primary cases and 57 recurrent cases,in which 32 were platinum-sensitive and 25 were platinum-resistant. The expression levels of BRCA1,PRP13,TUBB3 and ERCC1 genes in all cancer tissues were examined by real-time quantitative PCR. Results No significant difference was observed in the relative expression levels of BRCA1,PRP13,TUBB3 and ERCC1 between patients with primary and with recurrent epithelial ovarian cancers（ all P 0. 05）. Nevertheless,the expression levels of BRCA1 and ERCC1 were significantly different between the drugsensitive and drug-resistant patients of recurrent epithelial ovarian cancer（ both P 0. 05）,while there was no significant difference in the expression levels of PRP13 and TUBB3 between patients of these two groups（ both P 0. 05）. Conclusion The expression of BRCA1 and ERCC1 genes is associated with drug resistance in patients with recurrent epithelial ovarian cancer.